Published in Gene Therapy Weekly, August 16th, 2001
While previous research demonstrated the importance of GATA-3 in the development of asthma by preventing Th2-mediated allergic airway inflammation in transgenic mice expressing dominant negative GATA-3 in T cells, it did not clarify whether GATA-3 played an effector roll or whether it could be used as a target for gene therapy. These questions were addressed by S. Finotto and colleagues, Brigham and Women's Hospital, Boston, Massachusetts.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.